Metastatic Lung Cancer with Jared M. Weiss, MD
Weiss case 2:
A 62 year-old neversmoker with stage IV adenocarcinoma
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More